114676-91-4

Basic information

• Product Name: 1,2-Pyrrolidinedicarboxylic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S,4R)-
• CAS NO: 114676-91-4
• Molecular Formula: C17H33NO5Si
• Molecular Weight: 359.538
• Mol File: 114676-91-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1,2-Pyrrolidinedicarboxylic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S,4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Pyrrolidinedicarboxylic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S,4R)-(114676-91-4)
• EPA Substance Registry System: 1,2-Pyrrolidinedicarboxylic acid, 4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, 1-(1,1-dimethylethyl) 2-methyl ester, (2S,4R)-(114676-91-4)

Safety Data

• Hazardous Substances Data: 114676-91-4(Hazardous Substances Data)

Usage

Molecular structure

The compound is composed of pyrrolidinedicarboxylic acid, a t-butyl dimethylsilyl group, and a 2-methyl ester.

Stereochemistry

The arrangement of atoms around the chiral centers is specified as (2S,4R)-.

Potential applications

The compound may have potential applications in pharmaceuticals, agrochemicals, or other industries due to its unique structure and properties.

Further research

Additional research and experimentation would be needed to fully understand and utilize the potential of this chemical.

Upstream product

• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 

Downstream Products

• 114676-93-6 (2R,4R)-tert-butyl 4-hydroxy-2-methylpyrrolidine-1-carboxylate 
• 114676-85-6 (2'R,4'S)-7-(4'-amino-2'-methylpyrrolidinyl)-1-(2,4-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride 
• 114676-83-4 (2'R,4'S)-7-(4'-amino-2'-methylpyrrolidinyl)-1-(2,4-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxoquinoline-3-carboxylic acid 
• 400724-42-7 (+)-menthyl (2S/R,4R)-2-benzyl-1-(tert-butoxycarbonyl)-4-(tert-butyldimethylsilyloxy)pyrrolidine-2-carboxylate 
• 400724-24-5 (+)-menthyl (2S,4R)-1-(tert-butoxycarbonyl)-4-(tert-butyldimethylsilyloxy)pyrrolidine-2-carboxylate 
• 400724-23-4 (-)-menthyl (2S,4R)-1-(tert-butoxycarbonyl)-4-(tert-butyldimethylsilyloxy)pyrrolidine-2-carboxylate 
• 561297-15-2 (2S,4R)-1-t-butoxycarbonyl-2-{1-hydroxy-1-[4-methoxyphenylmethyl]}-4-[t-butyldimethylsilyloxy]pyrrolidine 
• 561297-16-3 (3R,5R)-5-(4-Methoxy-benzyl)-pyrrolidin-3-ol 
• 338386-44-0 C₂₆H₃₄N₂O₄ 
• 338386-49-5 C₂₆H₃₆N₂O₃ 

Relevant articles and documents

Design, synthesis, and antileukemic activity of stereochemically defined constrained analogues of FTY720 (Gilenya)

FTY720 functions as an immunosuppressant due to its effect on sphingosine-1-phosphate receptors. At doses well above those needed for immunosuppression, FTY720 also has antineoplastic actions. Our published work suggests that at least some of FTY720's anticancer activity is independent of its effects on S1P receptors and due instead to its ability to induce nutrient transporter down-regulation. Compounds that trigger nutrient transporter loss but lack FTY720's S1P receptor-related, dose-limiting toxicity have the potential to be effective and selective antitumor agents. In this study, a series of enantiomerically pure and stereochemically diverse O-substituted benzyl ethers of pyrrolidines was generated and tested for the ability to kill human leukemia cells. The stereochemistry of the hydroxymethyl was found to be a key determinant of compound activity. Moreover, phosphorylation of this group was not required for antileukemic activity.

Amino 6-membered ring derivative and pharmaceutical applications thereof including the use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor

The present invention relates to an amino 6-membered ring derivative and pharmaceutical applications thereof, which specifically relates to the amino 6-membered ring derivative represented by the general formula (I) or stereoisomers thereof, pharmaceutically acceptable salts thereof, a prodrug, a pharmaceutical composition comprising the derivative, and the pharmaceutical use for manufacturing dipeptidyl peptidase-4(IDPP-IV) inhibitor, wherein the definition of each substituent in the general formula (I) is the same as described in the specification.

A METHOD OF TREATING LIVER FIBROSIS

The present invention relates to a method of treating hepatis C and/or liver fibroisis with 3-cycloalkylaminopyrrolidine derivatives of the present invention